PTC Therapeutics or Eli Lilly: Which Stock Has More Upside?
Eli Lilly fell -5.9% during the past Day. You may be tempted to buy more, or may want to reduce your exposure. But there is an entirely different perspective you might be missing. Is there a better alternative? Turns out, its peer PTC Therapeutics gives you more. PTC Therapeutics (PTCT) stock offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Eli Lilly (LLY) stock, suggesting you may be better off investing in PTCT
- PTCT’s Last 12 Months revenue growth was 114.5%, vs. LLY’s 44.7%.
- In addition, its Last 3-Year Average revenue growth came in at 44.9%, ahead of LLY’s 32.1%.
- PTCT’s LTM margin is higher: 49.5% vs. LLY’s 45.6%.
These differences become even clearer when you look at the financials side by side. The table highlights how LLY’s fundamentals stack up against those of PTCT on growth, margins, momentum, and valuation multiples.
Valuation & Performance Overview
| LLY | PTCT | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 28.1 | 6.5 | PTCT |
| Revenue Growth | |||
| Last Quarter | 42.6% | -22.7% | LLY |
| Last 12 Months | 44.7% | 114.5% | PTCT |
| Last 3 Year Average | 32.1% | 44.9% | PTCT |
| Operating Margins | |||
| Last 12 Months | 45.6% | 49.5% | PTCT |
| Last 3 Year Average | 37.9% | -2.0% | LLY |
| Momentum | |||
| Last 3 Year Return | 189.0% | 42.6% | LLY |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: LLY Revenue Comparison | PTCT Revenue Comparison
See more margin details: LLY Operating Income Comparison | PTCT Operating Income Comparison
- Beyond Price Action: Does DG Offer Genuine Diversification?
- Kyndryl Stock: Strong Cash Flow Poised for a Re-Rating?
- S&P Global Stock Pays Out $29 Bil – Investors Take Note
- General Motors Stock Hands $29 Bil Back – Worth a Look?
- Coinbase Global Stock Testing Price Floor – Buy Now?
- Intuit Stock Near Crucial Support – Buy Signal?
See detailed fundamentals on Buy or Sell PTCT Stock and Buy or Sell LLY Stock. Below we compare market return and related metrics across years.
Historical Market Performance
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| LLY Return | 66% | 34% | 61% | 33% | 40% | -8% | 518% | <=== | |
| PTCT Return | -35% | -4% | -28% | 64% | 68% | -12% | 9% | ||
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -2% | 78% | ||
| Monthly Win Rates [3] | |||||||||
| LLY Win Rate | 58% | 75% | 58% | 58% | 58% | 33% | 57% | ||
| PTCT Win Rate | 33% | 58% | 42% | 83% | 58% | 0% | 46% | ||
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | 60% | <=== | |
| Max Drawdowns [4] | |||||||||
| LLY Max Drawdown | -3% | -15% | -15% | 0% | -19% | -9% | -10% | ||
| PTCT Max Drawdown | -42% | -36% | -53% | -12% | -20% | -17% | -30% | ||
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -3% | -8% | <=== | |
[1] Cumulative total returns since the beginning of 2021
[2] 2026 data is for the year up to 3/17/2026 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read PTCT Dip Buyer Analyses to see how the stock has fallen and recovered in the past.
Still not sure about LLY or PTCT? Consider portfolio approach.
Portfolios Are The Smarter Way To Invest
Single stocks swing wildly but staying invested matters. A well built portfolio helps you stay invested, captures upside and softens the blows from individual stocks.
Beating the market consistently is hard, but the Trefis High Quality (HQ) Portfolio makes it look achievable. By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000. See how this curated selection delivers superior risk-adjusted returns in our detailed performance factsheet.